- Posts by Jean-Claude Velasquez
Associate“The law was my second career—health care was my first. That experience shapes how I approach every client matter: with an understanding of the strategic and operational realities that give legal advice its meaning.” ...
On May 21, 2025, the Centers for Medicare & Medicaid Services (CMS) announced[1] an aggressive plan (Plan) to expand its efforts to address fraud, waste, and abuse in Medicare Advantage (MA). By engaging with enhanced technology and significantly expanding its workforce, CMS states that it intends to audit every eligible MA contract for Payment Years (PY) 2018 through 2024 and recover on all prior audits conducted by CMS and the Office of Inspector General (OIG). Historically, CMS has only selected a small subset of contracts (approximately sixty) for each PY audited. CMS is currently completing PY2018 Risk Adjustment Data Validation (RADV) audit but has yet to issue findings or payment recovery demands for any audit completed. CMS has similarly not taken material action regarding the so called “OIG audits”.
Background
CMS Audit Methodology. CMS officially launched its RADV audit program in 2008. The audit methodology employed by CMS has evolved over the years through various rule making efforts and sub-regulatory issuances. CMS’s proposed rule in 2010 set forth an audit methodology to review a risk stratified 201-member sample, where all risk adjusted Hierarchical Condition Categories (HCCs) for each member would be reviewed and checked for errors.[2] Finalizing this methodology in 2012[3], CMS then conducted audits on PY2012 and 2013 utilizing this approach. The presumption was that CMS would extrapolate and recoup such amounts. However, CMS did not issue final agency actions requiring substantial repayments or extrapolation.
Recent Updates
- Watch: Gender-Affirming Care: What Health Care Providers Need to Know About Federal Enforcement – Thought Leaders in Health Law
- Executive Order 14321 at One Year: Civil Commitment Policy Shifts and Provider Impact
- Watch: FDA’s 2026 Enforcement Priorities: What In-House Counsel Must Know – Thought Leaders in Health Law
- The Future of 340B: New Bills Offer Competing Solutions to Modernize the 340B Drug Discount Program
- "Enough Is Enough": HHS-OIG Freezes Funds for New York Medicaid Fraud Control Unit, Effective July 1